Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Front Pediatr ; 12: 1441891, 2024.
Artigo em Inglês | MEDLINE | ID: mdl-39350791

RESUMO

Introduction: Exposure to a range of anti-seizure medications (ASMs) during early brain development adversely impacts neurodevelopmental outcomes in both animal models and in clinical studies. Many ASMs, including phenobarbital, phenytoin, valproate (VPA), and benzodiazepines, are associated with acute neurotoxicity (cell death), impaired synaptic development, and long-term behavioral changes following gestational or neonatal exposure in animals. This is mirrored in clinical studies which show lasting neurodevelopmental deficits following early-life or gestational exposure to these drugs. Brivaracetam (BRV) and perampanel (PER) are two newer generation anti-seizure medications and are of interest based on their mechanisms of action (SV2A modulator, AMPA antagonist, respectively), as other drugs with these mechanisms of action do not trigger acute neurotoxicity. Both BRV and PER show anti-seizure efficacy in developing animals, but potential neurotoxicity of these drugs is unexplored. Methods: To address this gap, we treated postnatal day (P)7 Sprague-Dawley rats with BRV (20, 40, 80 mg/kg) and PER (0.1, 0.9, 2.7 mg/kg), and assessed the induction of cell death across a range of vulnerable brain regions 24 h after exposure. Cell death was assessed using pathogreen staining. Results: In each of the regions examined (dorsal striatum, nucleus accumbens, motor cortex, cingulate cortex, lateral thalamus, septum, hippocampus), VPA, which served as a positive control, significantly increased cell death as measured by the numer of pathogreen positive cells. By contrast, neither BRV nor PER increased the number of pathogreen positive cells in any region examined. Discussion: Our results suggest that BRV and PER may have a positive safety profile-at least with respect to acute induction of cell death - and therefore may offer a safer option for the treatment of early life seizures.

2.
Epilepsy Behav ; 158: 109898, 2024 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-39002273

RESUMO

GABA modulators such as phenobarbital (PB) and sodium channel blockers such as phenytoin (PHT) have long been the mainstay of pharmacotherapy for the epilepsies. In the context of neonatal seizures, both PB and PHT display incomplete clinical efficacy. Moreover, in animal models, neonatal exposure to these medications result in neurodegeneration raising concerns about safety. Cenobamate, a more recently approved medication, displays unique pharmacology as it is both a positive allosteric modulator of GABA-A receptors, and a voltage-gated sodium channel blocker. While cenobamate is approved for adult use, its efficacy and safety profile against neonatal seizures is poorly understood. To address this gap, we assessed the efficacy and safety of cenobamate in immature rodents. Postnatal day (P)7 rat pups were pretreated with cenobamate and challenged with the chemoconvulsant pentylenetetrazole (PTZ) to screen for anti-seizure effects. In a separate experiment, P7 rats were treated with cenobamate, and brains were processed to assess induction of cell death. Cenobamate displays dose-dependent anti-seizure efficacy in neonatal rats. Unlike PHB and PHT, it does not induce neurotoxicity in P7 rats. Thus, cenobamate may be effective at treating neonatal seizures while avoiding unwanted neurotoxic side effects such as cell death.


Assuntos
Animais Recém-Nascidos , Anticonvulsivantes , Carbamatos , Morte Celular , Modelos Animais de Doenças , Relação Dose-Resposta a Droga , Ratos Sprague-Dawley , Convulsões , Animais , Convulsões/induzido quimicamente , Convulsões/tratamento farmacológico , Anticonvulsivantes/farmacologia , Ratos , Morte Celular/efeitos dos fármacos , Carbamatos/farmacologia , Carbamatos/uso terapêutico , Clorofenóis/farmacologia , Pentilenotetrazol/toxicidade , Masculino , Feminino , Convulsivantes/toxicidade , Encéfalo/efeitos dos fármacos , Tetrazóis
3.
Proc Biol Sci ; 286(1916): 20192347, 2019 12 04.
Artigo em Inglês | MEDLINE | ID: mdl-31795869

RESUMO

Like many animals, tadpoles often produce different, predator-specific phenotypes when exposed to risk of predation. It is generally assumed that such plasticity enhances survival in the presence of the predator and is costly elsewhere, but evidence remains surprisingly scarce. We measured (1) the survival trade-off of opposing phenotypes developed by Dendropsophus ebraccatus tadpoles when exposed to different predators and (2) which specific aspects of morphology drive any potential survival benefit or cost. Tadpoles developed predator-specific phenotypes after being reared with caged fish or dragonfly predators for two weeks. In 24 h predation trials with either a fish or a dragonfly, survival was highest in the groups with their matched predator, and lowest among with those the mismatched predator, with predator-naive controls being relatively intermediate. Then, using a large group of phenotypically variable predator-naive tadpoles, we found that increased survival rates are directly related to the morphological changes that are induced by each predator. This demonstrates that induced phenotypes are indeed adaptive and the product of natural selection. Furthermore, our data provide clear evidence of an environmental cost for phenotypic plasticity in a heterogeneous environment. Such costs are fundamental for understanding the evolution and maintenance of inducible phenotypes.


Assuntos
Larva/anatomia & histologia , Fenótipo , Comportamento Predatório , Animais , Anuros , Odonatos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA